# Cardlytics, Inc.: financial statements, quarterly

CDLX · Nasdaq · CIK 1666071 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cdlx.md) · [Financials](/companies/cdlx/financials.md) · [Filings](/companies/cdlx/filings.md) · [Insiders](/companies/cdlx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cdlx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [73.1](/filings/0001666071-24-000167.md) | [82.6 d](/filings/0001666071-26-000010.md) | [62.2](/filings/0001666071-25-000069.md) | [64.0](/filings/0001666071-25-000126.md) | [61.1](/filings/0001666071-25-000159.md) | [68.3 d](/filings/0001666071-26-000010.md) | [56.4](/filings/0001628280-26-032158.md) | [58.0](/filings/0001628280-26-053340.md) | [47.0](/filings/0001666071-25-000159.md) | [50.9 d](/filings/0001666071-26-000010.md) | [34.3](/filings/0001628280-26-032158.md) | [36.9](/filings/0001628280-26-053340.md) |
| Research and development | $m | [12.4](/filings/0001666071-24-000167.md) | [12.5 d](/filings/0001666071-26-000010.md) | [13.0](/filings/0001666071-25-000069.md) | [13.5](/filings/0001666071-25-000126.md) | [13.2](/filings/0001666071-25-000159.md) | [9.9 d](/filings/0001666071-26-000010.md) | [10.3](/filings/0001628280-26-032158.md) | [9.9](/filings/0001628280-26-053340.md) | [8.8](/filings/0001666071-25-000159.md) | [8.0 d](/filings/0001666071-26-000010.md) | [6.4](/filings/0001628280-26-032158.md) | [5.5](/filings/0001628280-26-053340.md) |
| Operating income | $m | [(20.7)](/filings/0001666071-24-000167.md) | [(103) d](/filings/0001666071-26-000010.md) | [(22.8)](/filings/0001666071-25-000069.md) | [(15.8)](/filings/0001666071-25-000126.md) | [(149)](/filings/0001666071-25-000159.md) | [(8.3) d](/filings/0001666071-26-000010.md) | [(11.1)](/filings/0001628280-26-032158.md) | [(9.6)](/filings/0001628280-26-053340.md) | [(68.9)](/filings/0001666071-25-000159.md) | [(6.1) d](/filings/0001666071-26-000010.md) | [(8.3)](/filings/0001628280-26-032158.md) | [(5.4)](/filings/0001628280-26-053340.md) |
| Interest expense | $m | not reported | not reported | [1.7](/filings/0001666071-25-000069.md) | [2.4](/filings/0001666071-25-000126.md) | [2.4](/filings/0001666071-25-000159.md) | [2.4 d](/filings/0001666071-26-000010.md) | [2.4](/filings/0001628280-26-032158.md) | [2.4](/filings/0001628280-26-053340.md) | [2.9](/filings/0001666071-25-000159.md) | [(18.3) d](/filings/0001666071-26-000010.md) | [2.8](/filings/0001628280-26-032158.md) | [2.5](/filings/0001628280-26-053340.md) |
| Income tax | $m | [0.0](/filings/0001666071-23-000150.md) | [0.0 d](/filings/0001666071-26-000010.md) | not reported | not reported | not reported | not reported | [0.0](/filings/0001628280-26-032158.md) | [0.0](/filings/0001628280-26-053340.md) | not reported | not reported | [0.0](/filings/0001628280-26-032158.md) | [0.0](/filings/0001628280-26-053340.md) |
| Net income | $m | [(24.0)](/filings/0001666071-24-000167.md) | [(101) d](/filings/0001666071-26-000010.md) | [(24.3)](/filings/0001666071-25-000069.md) | [(4.3)](/filings/0001666071-25-000126.md) | [(145)](/filings/0001666071-25-000159.md) | [(15.6) d](/filings/0001666071-26-000010.md) | [(13.3)](/filings/0001628280-26-032158.md) | [(9.3)](/filings/0001628280-26-053340.md) | [(72.7)](/filings/0001666071-25-000159.md) | [(8.3) d](/filings/0001666071-26-000010.md) | [(4.5)](/filings/0001628280-26-032158.md) | [(14.9)](/filings/0001628280-26-053340.md) |
| Diluted EPS | $ per share | [(0.63)](/filings/0001666071-24-000167.md) | not reported | [(0.56)](/filings/0001666071-25-000069.md) | [(0.09)](/filings/0001666071-25-000126.md) | [(2.90)](/filings/0001666071-25-000159.md) | not reported | [(0.26)](/filings/0001666071-25-000069.md) | [(0.18)](/filings/0001666071-25-000126.md) | [(1.36)](/filings/0001666071-25-000159.md) | not reported | not reported | not reported |
| Basic EPS | $ per share | [(0.63)](/filings/0001666071-24-000167.md) | not reported | [(0.56)](/filings/0001666071-25-000069.md) | [(0.09)](/filings/0001666071-25-000126.md) | [(2.90)](/filings/0001666071-25-000159.md) | not reported | [(0.26)](/filings/0001666071-25-000069.md) | [(0.18)](/filings/0001666071-25-000126.md) | [(1.36)](/filings/0001666071-25-000159.md) | not reported | not reported | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [90.1](/filings/0001666071-24-000167.md) | [91.8](/filings/0001666071-26-000010.md) | [97.8](/filings/0001666071-24-000094.md) | [71.2](/filings/0001666071-24-000130.md) | [67.0](/filings/0001666071-24-000167.md) | [65.6](/filings/0001666071-26-000010.md) | [52.0](/filings/0001666071-25-000069.md) | [46.7](/filings/0001666071-25-000126.md) | [44.0](/filings/0001666071-25-000159.md) | [48.7](/filings/0001628280-26-053340.md) | [35.7](/filings/0001628280-26-032158.md) | [28.0](/filings/0001628280-26-053340.md) |
| Current assets | $m | [206](/filings/0001666071-23-000150.md) | [224](/filings/0001666071-25-000034.md) | [218](/filings/0001666071-24-000094.md) | [185](/filings/0001666071-24-000130.md) | [183](/filings/0001666071-24-000167.md) | [178](/filings/0001666071-26-000010.md) | [157](/filings/0001666071-25-000069.md) | [150](/filings/0001666071-25-000126.md) | [141](/filings/0001666071-25-000159.md) | [137](/filings/0001628280-26-053340.md) | [129](/filings/0001628280-26-032158.md) | [101](/filings/0001628280-26-053340.md) |
| Total assets | $m | [635](/filings/0001666071-23-000150.md) | [574](/filings/0001666071-25-000034.md) | [569](/filings/0001666071-24-000094.md) | [534](/filings/0001666071-24-000130.md) | [399](/filings/0001666071-24-000167.md) | [393](/filings/0001666071-26-000010.md) | [369](/filings/0001666071-25-000069.md) | [361](/filings/0001666071-25-000126.md) | [293](/filings/0001666071-25-000159.md) | [286](/filings/0001628280-26-053340.md) | [264](/filings/0001628280-26-032158.md) | [235](/filings/0001628280-26-053340.md) |
| Current liabilities | $m | [179](/filings/0001666071-23-000150.md) | [171](/filings/0001666071-25-000034.md) | [103](/filings/0001666071-24-000094.md) | [105](/filings/0001666071-24-000130.md) | [156](/filings/0001666071-24-000167.md) | [149](/filings/0001666071-26-000010.md) | [132](/filings/0001666071-25-000069.md) | [129](/filings/0001666071-25-000126.md) | [124](/filings/0001666071-25-000159.md) | [78.4](/filings/0001628280-26-053340.md) | [59.4](/filings/0001628280-26-032158.md) | [62.4](/filings/0001628280-26-053340.md) |
| Total liabilities | $m | [410](/filings/0001666071-23-000150.md) | [439](/filings/0001666071-25-000034.md) | [370](/filings/0001666071-24-000094.md) | [324](/filings/0001666071-24-000130.md) | [330](/filings/0001666071-24-000167.md) | [323](/filings/0001666071-26-000010.md) | [305](/filings/0001666071-25-000069.md) | [302](/filings/0001666071-25-000126.md) | [298](/filings/0001666071-25-000159.md) | [292](/filings/0001628280-26-053340.md) | [268](/filings/0001628280-26-032158.md) | [251](/filings/0001628280-26-053340.md) |
| Long-term debt | $m | [257](/filings/0001666071-23-000150.md) | [258](/filings/0001666071-24-000167.md) | [258](/filings/0001666071-24-000094.md) | [213](/filings/0001666071-24-000130.md) | [213](/filings/0001666071-24-000167.md) | [214](/filings/0001666071-25-000159.md) | [214](/filings/0001666071-25-000069.md) | [214](/filings/0001666071-25-000126.md) | [215](/filings/0001666071-25-000159.md) | [209](/filings/0001628280-26-053340.md) | [204](/filings/0001628280-26-032158.md) | [184](/filings/0001628280-26-053340.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | [30.0](/filings/0001666071-23-000150.md) | [0.0](/filings/0001666071-25-000034.md) | not reported | not reported | [45.8](/filings/0001666071-24-000167.md) | [45.9](/filings/0001666071-26-000010.md) | [45.9](/filings/0001666071-25-000069.md) | [46.0](/filings/0001666071-25-000126.md) | [46.1](/filings/0001666071-25-000159.md) | [0.0](/filings/0001666071-26-000010.md) | not reported | not reported |
| Shareholders' equity | $m | [225](/filings/0001666071-24-000167.md) | [135](/filings/0001666071-26-000010.md) | [199](/filings/0001666071-25-000126.md) | [210](/filings/0001666071-25-000159.md) | [69.7](/filings/0001666071-25-000159.md) | [70.0](/filings/0001628280-26-053340.md) | [64.1](/filings/0001628280-26-053340.md) | [58.7](/filings/0001628280-26-053340.md) | [(4.7)](/filings/0001666071-25-000159.md) | [(6.5)](/filings/0001628280-26-053340.md) | [(4.0)](/filings/0001628280-26-053340.md) | [(16.0)](/filings/0001628280-26-053340.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: not reported
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [1.2 d](/filings/0001666071-24-000167.md) | [2.9 d](/filings/0001666071-26-000010.md) | [(17.6)](/filings/0001666071-25-000069.md) | [4.4 d](/filings/0001666071-25-000126.md) | [1.4 d](/filings/0001666071-25-000159.md) | [3.0 d](/filings/0001666071-26-000010.md) | [(6.7)](/filings/0001628280-26-032158.md) | [1.2 d](/filings/0001628280-26-053340.md) | [1.8 d](/filings/0001666071-25-000159.md) | [13.0 d](/filings/0001666071-26-000010.md) | [(5.6)](/filings/0001628280-26-032158.md) | [(8.6) d](/filings/0001628280-26-053340.md) |
| Capital expenditure | $m | [0.1 d](/filings/0001666071-24-000167.md) | [0.3 d](/filings/0001666071-26-000010.md) | [0.7](/filings/0001666071-25-000069.md) | [0.3 d](/filings/0001666071-25-000126.md) | [0.5 d](/filings/0001666071-25-000159.md) | [0.1 d](/filings/0001666071-26-000010.md) | [0.1](/filings/0001628280-26-032158.md) | [0.3 d](/filings/0001628280-26-053340.md) | [0.0 d](/filings/0001666071-25-000159.md) | [0.0 d](/filings/0001666071-26-000010.md) | [0.0](/filings/0001628280-26-032158.md) | [0.0 d](/filings/0001628280-26-053340.md) |
| Share repurchases | $m | [0.1 d](/filings/0001666071-24-000167.md) | [(0.1) d](/filings/0001666071-25-000034.md) | not reported | not reported | [0.1 d](/filings/0001666071-25-000159.md) | [(0.3) d](/filings/0001666071-25-000034.md) | not reported | not reported | [0.0 d](/filings/0001666071-25-000159.md) | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [33.3](/filings/0001666071-23-000150.md) | [36.7](/filings/0001666071-24-000094.md) | [34.9](/filings/0001666071-24-000130.md) | [38.0](/filings/0001666071-24-000167.md) | [43.2](/filings/0001666071-25-000069.md) | [49.1](/filings/0001666071-25-000126.md) | [50.0](/filings/0001666071-25-000159.md) | [51.9](/filings/0001628280-26-032158.md) | [5.3](/filings/0001628280-26-053340.md) | [53.5](/filings/0001666071-25-000159.md) | [54.9](/filings/0001628280-26-032158.md) | [5.8](/filings/0001628280-26-053340.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 5,888,716 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001628280-26-053340.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.